New registration is on HOLD till 30th April 2018.
1
Jakavi (ruxolitinib) is the first and only FDA-approved treatment for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea1. Ruxolitinib (trade name Jakavi) is a drug for the treatment of intermediate or high-risk myelofibrosis,Get suppliers, exporters, price or buy online Ledipasvir Sofosbuvir Ledifos Tablets from India. Ledipasvir 90 mg and Sofosbuvir 400 mg exporters India. Read more- https://www.hcvmedicine.com/jakavi/